BridgeMD
Tests treatment safety and results for Tinea Corporis
Official title A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis
ClinicalTrials.gov ID: NCT07312604
What this study is testing
What is Intra-Lesional MMR Immunotherapy?
Intra-Lesional MMR Immunotherapy is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for tinea corporis.
Also referred to as MMR Vaccine, Measles-Mumps-Rubella Vaccine.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This pilot study will test intra-lesional immunotherapy (MMR vaccine) injections as a treatment for recalcitrant tinea cruris and corporis in patients aged 10-60 years who have not improved with standard antifungal treatments. \ Eligibility: Participants must have recalcitrant tinea, defined as: Rapid progression or large areas of skin affected, Infection in multiple family members, especially females and children Rapid relapse after prior treatment Suspected resistant T.
- Time commitment: about 6 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 10 to 60
You may be able to join if
- Age between 10 - 60 years.
- Evidence of recalcitrant tinea e.g. (rapid progression \& large areas affected of the body, affection of more than one family members especially...
- Patients failed at least 2 courses of systemic antifungal therapy in the last 3 months.
- Safe contraception during the study (for females in the childbearing period).
You likely can't join if
- Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.
- Age \ 60 years.
- Immunocompromised patients e.g. (uncontrolled DM or HIV patients).
- Naïve patients without previous systemic antifungal treatment.
- Unreliable patients.
The study team makes the final eligibility decision.
Where it's taking place
- Al Mansurah, Dakahlia Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 10 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Al Mansurah, Dakahlia Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.